Compare Adaptive Biotechnologies Corp (ADPT) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Avantis US Small Cap Value ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Avantis US Small Cap Value ETF trades at $122.58. The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | AVUV | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $124.94 |
52-Week Low | $10.24 | $90.37 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AVUV trades at $123.82, up 0.25% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF's small-cap value focus has gained attention amid a market rotation, with recent news highlighting its outperformance versus growth peers and potential benefits from shifting rate expectations. Support and resistance levels are closely watched near current prices.
The outlook for AVUV hinges on continued small-cap value strength, though exposure to regional banks and sensitivity to interest rates pose risks. Its active management approach aims to capture the value premium, but elevated volatility relative to large-caps remains a consideration for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
